Choline magnesium trisalicylate
- Generic Name
- Choline magnesium trisalicylate
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29MgNO10
- CAS Number
- 64425-90-7
- Unique Ingredient Identifier
- -
- Background
Choline magnesium trisalicylate is a non-acetylated salicylate used widely as a nonsteroidal anti-inflammatory drug. Trisalicylate significantly reduces methotrexate renal clearance, displacing methotrexate from protein, increasing the fraction unbound by 28% .
- Indication
Choline magnesium trisalicylate is used to reduce pain and inflammation caused by conditions such as arthritis. This medication is also used to treat fever in adults.
- Associated Conditions
- Fever, Juvenile Idiopathic Arthritis (JIA), Mild pain, Osteoarthritis (OA), Rheumatoid Arthritis, Acute Shoulder Pain, Articular inflammation, Moderate Pain
- Associated Therapies
- -
Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia in RemissionAdult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Interventions
- First Posted Date
- 2014-05-22
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 27
- Registration Number
- NCT02144675
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 1
- Registration Number
- NCT01009931
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 15
- Registration Number
- NCT00156299
- Locations
- 🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.